Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00096434 | Sorafenib in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2024 | clinicaltrials |
| A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer |
| completed |
| Phase 2 |
| 90 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Mar 6, 2024 |
| clinicaltrials |
| NCT03752723 | Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) | completed | Phase 1 / Phase 2 | 84 | Genexine, Inc.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT00618657 | Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | completed | Phase 2 | 127 | University of California, IrvineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02954055 | MEtronomic TrEatment Option in Advanced bReast cAncer(METEORA-II) | completed | Phase 2 | 140 | ETOP IBCSG Partners FoundationNETWORK | 1 | Feb 26, 2024 | clinicaltrials |
| NCT00712881 | Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer | completed | Phase 2 | 126 | Cephalon, Inc.INDUSTRY | 6 | Feb 23, 2024 | clinicaltrials |
| NCT02971761 | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03853707 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04240106 | Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)(LUZERN) | completed | Phase 2 | 14 | MedSIROTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT02456857 | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT00482755 | Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | completed | Phase 2 | 4 | NCIC Clinical Trials GroupNETWORK | 1 | Feb 12, 2024 | clinicaltrials |
| NCT03878823 | Safety and Pharmacokinetics of ODM-209(STESIDES) | completed | Phase 1 / Phase 2 | 38 | Orion Corporation, Orion PharmaINDUSTRY | 3 | Feb 1, 2024 | clinicaltrials |
| NCT03306472 | A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer(PIONEER) | completed | Phase 2 | 198 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT00204477 | Soy Protein and Breast Cancer Risk Reduction | completed | Phase 2 | 321 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03312738 | A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor(BOLERO-5) | completed | Phase 2 | 159 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04596150 | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer | completed | Phase 2 | 125 | CytomX TherapeuticsINDUSTRY | 3 | Jan 23, 2024 | clinicaltrials |
| NCT04805736 | Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer | completed | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04983238 | Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 | completed | Phase 1 / Phase 2 | 48 | Byondis B.V.INDUSTRY | 3 | Jan 5, 2024 | clinicaltrials |
| NCT03742986 | Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) | completed | Phase 2 | 8 | NYU Langone HealthOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT03052634 | A Study of RC48-ADC in Subjects With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 112 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT02027818 | Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy | completed | Phase 2 | 20 | Jules Bordet InstituteOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT02834403 | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 37 | The Methodist Hospital Research InstituteOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03831711 | 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 5 | Andrei IagaruOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02297698 | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients(HER3+) | completed | Phase 2 | 100 | Cancer Insight, LLCINDUSTRY | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT01387295 | Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease | completed | Phase 2 | 38 | Dorte NielsenOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT02636582 | Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04150731 | 16α-18F-fluor-17β-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer | completed | Phase 1 / Phase 2 | 8 | University of AarhusOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT00006256 | Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer | completed | Phase 2 | 44 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT01142401 | Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | completed | Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Nov 27, 2023 | clinicaltrials |
| NCT00525759 | Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer(ANZAC) | completed | Phase 2 | 40 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03481998 | A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 104 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT03054363 | Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer | completed | Phase 1 / Phase 2 | 42 | University of Colorado, DenverOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT00634634 | Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03358017 | Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer(YAPPETIZER) | completed | Phase 2 | 54 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT01622868 | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 3 | Oct 17, 2023 | clinicaltrials |
| NCT04465097 | Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer(NeoTEE) | completed | Phase 2 | 30 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00577122 | Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer | completed | Phase 2 | 30 | Indiana UniversityOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT02068092 | Olive Oil for High Risk Breast Cancer Prevention in Women | completed | Phase 2 / Phase 3 | 51 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03121352 | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT00499083 | Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) | completed | Phase 2 | 17 | University of NebraskaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT01106898 | Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery | completed | Phase 2 | 112 | University of NebraskaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02101385 | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | completed | Phase 2 | 193 | Bryan Schneider, MDOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00591851 | Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | completed | Phase 2 | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT00082641 | Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer | completed | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04032080 | LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer | completed | Phase 2 | 10 | Baylor Research InstituteOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT03809988 | PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)(PALMIRA) | completed | Phase 2 | 198 | MedSIROTHER | 6 | Sep 7, 2023 | clinicaltrials |
| NCT02028364 | Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women(PEARL) | completed | Phase 2 | 55 | Jules Bordet InstituteOTHER | 1 | Aug 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 8, 2024source: clinicaltrials